Preliminary results of a randomized multicenter controlled trial comparing interferon (IFN) thrice weekly in combination with ribavirin (RBV) with interferon daily in combination with ribavirin and amantadine (AMA) in the treatment of chronic hepatitis C in human immune deficiency virus (HIV) co-infected patients.

被引：0
|
作者：
Puoti, M
Zanini, B
Quinizan, P
Santantonio, T
Cavaliere, R
Roldan, EQ
Castelli, F
Suter, F
Pastore, G
Carosi, G
机构：
[1] Univ Brescia, AO Spedali Civili Brescia, MaSTer HIV HCV Coinfect Study Grp, Brescia, Italy
[2] Osped Riuniti Bergamo, Div Malattie Infett, I-24100 Bergamo, Italy
[3] Univ Bari, Clin Malattie Infett, Bari, Italy
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1692
引用
下载
收藏
页码：586A / 586A
页数：1
相关论文
共 50 条
  • [31] Efficacy of daily interferon-alpha-2b (IFN-α) in combination with ribavirin in the treatment of naive patients with chronic hepatitis C (CHC):: A randomised controlled trial.
    Tassopoulos, NC
    Ioannis, K
    Tsantoulas, D
    Raptopoulou, M
    Paraskevas, E
    Hatzis, G
    Vafiadis, I
    Chrysagis, D
    Kanatakis, S
    Akriviadis, E
    Sypsa, V
    Hatzakis, A
    HEPATOLOGY, 2001, 34 (04) : 334A - 334A
  • [32] A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs interferon α-2a and ribavirin in treatment-naive patients with chronic hepatitis C
    Mangia, A
    Ricci, GL
    Persico, M
    Minerva, N
    Carretta, V
    Bacca, D
    Cela, M
    Piattelli, M
    Annese, M
    Maio, G
    Conte, D
    Guadagnino, V
    Pazienza, V
    Festi, D
    Spirito, F
    Andriulli, A
    JOURNAL OF VIRAL HEPATITIS, 2005, 12 (03) : 292 - 299
  • [33] Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study
    Milazzo, Laura
    Caramma, Ilaria
    Mazzali, Cristina
    Cesari, Miriam
    Olivetti, Micol
    Galli, Massimo
    Antinori, Spinello
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (04) : 735 - 740
  • [34] Once-weekly recombinant human erythropoetin (epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus (HCV)-infected patients receiving interferon-α-2b (IFN)/RBV combination therapy
    Dieterich, DT
    Wasserman, R
    Brau, N
    Hassanein, TI
    Bini, EJ
    Sulkowski, M
    GASTROENTEROLOGY, 2001, 120 (05) : A64 - A64
  • [35] Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus coinfected patients treated with interferon/ribavirin:: A randomized controlled trial
    Sulkowski, MS
    Dieterich, DT
    Bini, EJ
    Bräu, N
    Alvarez, D
    DeJesus, E
    Leitz, GJ
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (04) : 504 - 506
  • [36] Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin:: differences between pegylated and standard interferon
    Arizcorreta, A
    Brun, F
    Fernández-Gutiérrez, C
    Juárez, RG
    Guerrero, F
    Pérez-Guzmán, E
    Girón-González, JA
    CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (12) : 1067 - 1074
  • [37] High-daily induction dose of interferon in combination with ribavirin in chronic hepatitis C non responder patients: A randomised controlled trial.
    Leroy, V
    Dutertre, N
    Tran, A
    Naveau, S
    Abergel, A
    Bourliere, M
    Plages, A
    Zarski, JP
    HEPATOLOGY, 2001, 34 (04) : 339A - 339A
  • [38] Interferon-α-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-α alone:: An Italian multicenter, randomized, controlled, clinical study
    Barbaro, G
    Di Lorenzo, G
    Soldini, M
    Giancaspro, G
    Bellomo, G
    Belloni, G
    Grisorio, B
    Annese, M
    Bacca, D
    Francavilla, R
    Rizzo, G
    Barbarini, G
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (12): : 2445 - 2451
  • [39] High-daily induction dose of interferon in combination with ribavirin in chronic hepatitis C (CHC) non responder patients: A randomised controlled trial
    Leroy, V
    Dutertre, N
    Tran, A
    Naveau, S
    Abergel, A
    Bronwicki, JP
    Bourliere, M
    Plages, A
    Roman, V
    Zarski, JP
    JOURNAL OF HEPATOLOGY, 2001, 34 : 146 - 146
  • [40] Daily or three times a week interferon alfa2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C, final results of a randomized prospective study
    de Ledinghen, V
    Trimoulet, P
    Winnock, M
    Foucher, J
    Chene, G
    Couzigou, P
    Bernard, P
    JOURNAL OF HEPATOLOGY, 2001, 34 : 138 - 138
12345